Updates

** Biotech firm Replimune REPL.O rise 28% to over-a-month high of $5.23, following a 9% gain on Tuesday

** Marty Makary resigned as U.S. FDA commissioner, President Donald Trump said on Tuesday, after weeks of clashes with the White House and health advisers

** Makary drew criticism after declining to approve a cancer treatment from Replimune, adding to industry concerns about unpredictability

** In the near team, Replimune and uniQure "could immediately benefit from the removal of regulatory headwinds tied to this particular leadership," said RBC analyst Brian Abrahams

** Makary also faced tensions with drugmakers, including disputes with UniQure over regulatory decisions

** U.S.-listed shares of Dutch gene therapy developer uniQure UQ1.F, QURE.O down 2.1% at $28.49, following a 5% gain on Tuesday

** He "was not industry‑friendly," notably after public criticism of QURE data - Truist analyst Danielle Brill

** As of last close, QURE up 21.6%, REPL down ~58% YTD